Press "Enter" to skip to content

Novavax espère toujours fabriquer un vaccin contre la COVID-19 au Canada

[Translated from French]

The last manufacturer to offer an alternative to COVID-19 mRNA vaccines in Canada hopes to meet the government’s 2024 deadline for domestic dose production.

Novavax, based in Maryland, USA, held a press conference on Wednesday to tout the safety and efficacy of its new vaccine, which targets newer strains of COVID-19.